Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Nano Today. 2023 Jan 3;48:101746. doi: 10.1016/j.nantod.2022.101746

Fig. 3. Development and validation of a panel of 11 PCa-relevant genes.

Fig. 3.

(a) Schematic flow of the selection of 11-gene panel for PCa EV Digital Scoring Assay, including ACP3, FOLH1, HOXB13, KLK2, KLK3, KLK4, MSMB, RLN1, SLC45A3, STEAP2, and TMPRSS2. (b) Box plot of the percentile of expression level of the 11-gene panel in primary PCa patients’ tissues from TCGA, PCa cell lines from CCLE, and immune cells from DMAP. Each dot represents the mean of percentile of each maker. *Expression of STEAP2, SLC45A3, and KLK4 are not available in DMAP. CCLE, Cancer Cell Line Encyclopedia; DMAP, Differentiation MAP dataset; EV, extracellular vesicle; PCa, prostate cancer; TCGA, The Cancer Genome Atlas.